Buy Rating Affirmed: Jasper Therapeutics' Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment Market
TipRanksApr 25 10:55
Jasper Therapeutics Analyst Ratings
BenzingaApr 3 19:32
Jasper Therapeutics Analyst Ratings
BenzingaMar 28 16:35
Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment
TipRanksMar 20 21:05
Analysts' Top Healthcare Picks: Jasper Therapeutics (JSPR), Alphatec Holdings (ATEC)
TipRanksMar 20 21:00
Jasper Therapeutics Analyst Ratings
BenzingaMar 18 20:33
Buy Rating for Jasper Therapeutics: Promising Prospects for Briquilimab in Treating Chronic Urticaria
TipRanksMar 18 17:45
Jasper Therapeutics Analyst Ratings
BenzingaMar 7 21:01
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)
TipRanksMar 7 20:41
Buy Rating Affirmed: Jasper Therapeutics' Progress and Potential in Addressing Unmet Needs in Chronic Urticaria Treatment
TipRanksMar 5 02:15
Oppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)
TipRanksFeb 27 20:48
Buy Rating on Jasper Therapeutics Highlighting Briquilimab's Potential in Chronic Urticaria Treatment
TipRanksFeb 27 03:25
Buy Rating for Jasper Therapeutics: Promising Developments in CSU Treatment Pipeline and Anticipated Clinical Milestones
TipRanksFeb 21 22:45
Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Maintains $6 Price Target
BenzingaOct 12, 2023 23:50
Jasper Therapeutics Analyst Ratings
BenzingaOct 12, 2023 23:46
Credit Suisse Reiterates Outperform on Jasper Therapeutics, Maintains $4 Price Target
BenzingaAug 14, 2023 20:08
Jasper Therapeutics Analyst Ratings
BenzingaAug 14, 2023 20:08
Capital One Initiates Coverage On Jasper Therapeutics With Overweight Rating, Announces Price Target of $7
BenzingaAug 11, 2023 22:27
Jasper Therapeutics Analyst Ratings
BenzingaAug 11, 2023 22:26
EF Hutton Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)
TipRanksJun 12, 2023 20:25
No Data
No Data